An mRNA COVID-19 vaccine does not increase the short-term risk of relapses in people with multiple sclerosis (MS), a new study indicates. Di Filippo et al. analysed data from 324 people with MS who received the Pfizer/BioNTech BNT162b2 vaccine and were followed up for ≥2 months after their first dose. The incidence of clinical relapses in the 2 months after vaccination did not differ significantly from that in the 2 months before vaccination. The results support the recommendation for people with MS to receive the COVID-19 vaccine.
References
Original article
Di Filippo, M. et al. mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry https://doi.org/10.1136/jnnp-2021-327200 (2021)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fyfe, I. Multiple sclerosis relapses not associated with mRNA COVID-19 vaccine. Nat Rev Neurol 17, 595 (2021). https://doi.org/10.1038/s41582-021-00561-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-021-00561-1